Finasteride - Moligand™, 10mM in DMSO , Steroid 5-alpha-reductase 2 inhibitor, CAS No.98319-26-7, Steroid 5-alpha-reductase 2 inhibitor

CAS: 98319-26-7 Cat. No.: F408197 Fórmula: C₂₃H₃₆N₂O₂ Peso molecular: 372.55 Número EC: 620-534-3

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

MK-906 | (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Finasteride Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with K i of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).
In vitro

Finasteride binds to the type 2 isozyme-NADPH complex to form a ternary complex with Ki of 1.19 nM, which then rearranges to a high affinity complex (E:I) with a pseudo first order rate constant of 1.62 ms. Finasteride dose-dependently inhibits the growth rate of the LnCap cell line. Finasteride markedly inhibits prostate-specific antigen (PSA) secretion and expression in LNCaP cells.

In vivo

Finasteride induces dosage-related incidences of hypospadias (penischisis) in male offspring with a threshold dosage level near 0.1 mg/kg/day and a 100% effect level of 100 mg/kg/day in male rats. Finasteride also causes decreased anogenital distance in male offspring in male rats. Finasteride and castration decreases prostate weight at day 21 by 65% and 93%, respectively, in rats. Finasteride has no significant effect on DNA content after 4 days and decreases DNA content by a maximum of 52% at 14 days in rats. Finasteride causes a less intense increase in staining in which 16% of epithelial cells stained for tissue transglutaminase on day 9 with a return to baseline by day 14 in rats. Finasteride-induced staining is less intense with peak staining at day 4 (0.7% of epithelial cells) and a return to control values by day 9 in rats.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinónimos

MK-906 | (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with K_i of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

INHIBITOR

Mecanismo de acción

Steroid 5-alpha-reductase 2 inhibitor

Propiedades del producto

• ALogP: 3

Nombres e identificadores

• Isómeros SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
• WGK Alemania: 3
• RTECS: CL5245000
• Peso molecular: 372.55
• Reaxy-Rn: 24866568
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24866568&ln=

Objetivos asociados (humanos)

CYP2C19 Tchem Cytochrome P450 2C19 (1 Activities)

Discover Target: CYP2C19

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SRD5A1 Tclin 3-oxo-5-alpha-steroid 4-dehydrogenase 1 (24 Activities)

Discover Target: SRD5A1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SRD5A2 Tclin 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (29 Activities)

Discover Target: SRD5A2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Propiedades químicas y físicas

• Punto de fusión (°C): 253°C

Referencias

1. Yao Wang, Lili Liu, Cheng Cheng, Shuxuan Wang, Qirui Zhai, Yunyang Song, Ronghua Dai.  (2023)  Study on mechanism of Zishen Pill treating benign prostatic hyperplasia based on serum pharmacochemistry and network pharmacology.  JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,      [PMID:37454501] [10.1016/j.jpba.2023.115480]

2. Jingru Zhao, Hong Xiang, Yurong Liu, Xiaoqing Miao.  (2025)  Positively charged chitosan-dissolving microneedles promote follicular accumulation of finasteride nanocrystals to treat androgenetic alopecia.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,      [PMID:40701470] [10.1016/j.ijbiomac.2025.146223]

3. Chi-Ming Liu, ZiChen Shao, XuZhou Chen, HanWu Chen, MengQiao Su, ZiWen Zhang, ZhengPing Wu, Peng Zhang, LiJie An, YinJie Jiang, Ai-Jun Ouyang.  (2023)  Neferine attenuates development of testosterone-induced benign prostatic hyperplasia in mice by regulating androgen and TGF-β/Smad signaling pathways.  SAUDI PHARMACEUTICAL JOURNAL,      [PMID:37293563] [10.1016/j.jsps.2023.05.004]

4. Rui Liu, Zhen Sun, Shimiao Wang, Xin Liu, Yuhong Man, Meiwan Chen, Qian Liu, Chunyue Wang.  (2024)  Wenshenqianlie capsule improves benign prostatic hyperplasia via its anti-inflammatory and antioxidant effects.  Aging-US,  16  (18): (12574).  [PMID:39237304] [10.18632/aging.206103]